Drugs / DYP688
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05415072 | Jul 2022 → Oct 2027 expected | uveal melanoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DYP688 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05415072 ↗ |
| Target | PMEL | “binds surface PMEL and delivers the potent Gαq/Gα11 (Gq/11) inhibitor SDZ475 as payload by internalization.” PMID 42443515 ↗ Jul 2026 |